NASDAQ: STEXStreamex Corp Stock
$6.27+0.17 (+2.79%)
Updated Sep 12, 2025
STEX Price
$6.27
Fair Value Price
-$0.00
Market Cap
$197.00M
52 Week Low
$0.40
52 Week High
$14.11
P/E
-6.09x
P/B
-54.46x
P/S
15,191.49x
PEG
N/A
Dividend Yield
N/A
Revenue
$13.00k
Earnings
-$26.20M
Gross Margin
100%
Operating Margin
-201,430.77%
Profit Margin
-201,892.3%
Debt to Equity
-31.3
Operating Cash Flow
-$4M
Beta
1.12
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
STEX Overview
BioSig Technologies, Inc. recently rebranded as Streamex Corp., effective September 12, 2025, following its merger with Streamex Exchange Corporation. The company shifted focus from healthcare technology to real-world asset tokenization, especially integrating the gold and commodities market into blockchain technology. Streamex provides institutional-grade infrastructure for tokenizing assets powered by a gold-denominated treasury.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine STEX's potential to beat the market
- STEX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important STEX news, forecast changes, insider trades & much more!
STEX News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how STEX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
STEX ($6.27) is overvalued by 333,690.11% relative to our estimate of its Fair Value price of -$0.00 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
STEX ($6.27) is not significantly undervalued (333,690.11%) relative to our estimate of its Fair Value price of -$0.00 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
STEX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more STEX due diligence checks available for Premium users.
Valuation
STEX fair value
Fair Value of STEX stock based on Discounted Cash Flow (DCF)
Price
$6.27
Fair Value
-$0.00
Undervalued by
333,690.11%
STEX ($6.27) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
STEX ($6.27) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
STEX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
STEX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.09x
Industry
31.61x
Market
36.98x
STEX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-54.46x
Industry
4.03x
STEX's financial health
Profit margin
Revenue
$0.0
Net Income
-$20.4M
Profit Margin
0%
STEX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
STEX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$109.7M
Liabilities
$113.2M
Debt to equity
-31.3
STEX's short-term liabilities ($113.20M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
STEX's short-term assets ($3.00M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
STEX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
STEX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.3M
Investing
$0.0
Financing
$0.0
STEX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
STEX vs Medical Device Stocks
Streamex Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.